March 9, 2022

(formerly Lumigan) is a drug that received FDA approval in 2008 as a treatment for hypotrichosis of the eyelashes, the condition of having inadequate or not enough eyelashes, and is marketed for both therapeutic and cosmetic purposes. 

Arizona therapeutically certified optometrists may prescribe a pharmaceutical agent for the treatment of an abnormal condition of the visual system but not for cosmetic purposes. Therefore, while “hypotrichosis” is a relative term, a licensed optometrist who holds a therapeutic pharmaceutical agents (PA) certificate may prescribe Latisse for a diagnosed condition of hypotrichosis supported by proper documentation in the patient’s record. Doctors holding only a DPA or TPA certificate may NOT prescribe Latisse.